ACIP votes to expand recommendation for Pfizer’s RSV vaccine Abrysvo to include adults aged 50 to 59 at increased risk of disease: New York Saturday, April 19, 2025, 10:00 Hrs [ ...

The Advisory Committee on Immunization Practices convened to make expanded vaccine recommendations amidst CDC leadership changes.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...